Studies have shown that novel tyrosine kinase inhibitors (TKIs), avapritinib and ripretinib, target the PDGFRA D842V mutation in GISTs and provide objective responses and long-term tumor control (21). This evidence concerns the gene PDGFRA and neoplasm.